Rasna Therapeutics, Inc. filed its 10-K/A on Jun 10, 2022 for the period ending Sep 30, 2021. In this report its auditor, Marcum LLP, gave an unqualified opinion expressing doubt that the company can continue as a going concern.
Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
0.0169 USD | +17.36% | +53.64% | +119.48% |
1st Jan change | Capi. | |
---|---|---|
+119.48% | 13.04M | |
+9.42% | 114B | |
+11.84% | 104B | |
-14.15% | 22.41B | |
-1.05% | 22.28B | |
-5.29% | 19.07B | |
-38.29% | 18B | |
-4.16% | 17.89B | |
+7.99% | 14.28B | |
+36.24% | 12.55B |
- Stock Market
- Equities
- RASP Stock
- News Actavia Life Sciences, Inc.
- Rasna Therapeutics, Inc. Auditor Raises 'Going Concern' Doubt